2018 IPO

Magenta Therapeutics Stock

Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.

Sign up today and learn more about Magenta Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Magenta Therapeutics Stock

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Funding History

November 2016$48.5M
May 2017$50.0M
April 2018$52.0M



Michael Cooke

VP and Head of Business Development

Christina Isacson

CEO, President & Co-Founder

Jason Gardner


Bastiano Sanna


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: